1 / 8

Serum Concentration

Serum Concentration. HCT116 cells NCI cultured in 5% FBS Nottingham cultured in 10% FBS Cultured in 5% for 1 week prior to experiment Drug dilutions carried out in appropriate FBS concentration. Serum Concentration. Treatment Length. HCT116 cells Same seeding density

anise
Download Presentation

Serum Concentration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Serum Concentration • HCT116 cells • NCI cultured in 5% FBS • Nottingham cultured in 10% FBS • Cultured in 5% for 1 week prior to experiment • Drug dilutions carried out in appropriate FBS concentration.

  2. Serum Concentration

  3. Treatment Length • HCT116 cells • Same seeding density • 72 or 48 h MTT assay • Time dependent activity • Previously shown for PMX 464 by A. Seaton

  4. Thioredoxin/Thioredoxin Reductase Insulin Reduction Assay – PMX 18034

  5. Thioredoxin/Thioredoxin Reductase Insulin Reduction Assay PMX 290, PMX 2058 and MESNA

  6. Thioredoxin/Thioredoxin Reductase Insulin Reduction Assay • Carry out further control experiments to try and explain inactivity in full Trx/TR insulin reduction assay • Alternative methods to ensure back-up screening does not miss inhibitors • Insulin reduction assay (EHC method) • Add substrate last rather than NADPH as inhibition of TR was dependent on presence of NADPH • Use rate of reaction rather than final OD • Requires 37 ºC • Direct TR/DTNB assay in parallel • Assess activity as well as expression levels in a panel of cell lines. • colon, breast, melanoma, pancreas

  7. Resistant Cells • HCT116 PMX 290 resistant cells • Growing in 0.8 mM (> 4 x GI50) • HCT116 Standard Therapy Resistant Cells • Irinotecan: currently growing in 0.85 mM (~ 1.7 x GI50) • 5-FU: currently recovering in drug free medium having stalled at 35 mM • IGROV1 Cisplatin resisiatant cells grown in 100 mM cisplatin • Not very resistant to cisplatin: IGROV1 GI50 = 3 mM • IGROV1 CISR GI50 = 5 mM • Remain sensitive to PMX 290

  8. Phosphatase Inhibition • Phosphatase activity in whole cell lysates of MCF7 and HCT116 cells • 1h treatment at 1 mM • 4-nitrophenyl phosphate as phosphatase substrate • yellow product

More Related